Key facts
- Ubrigene’s last known valuation is $50.8M (Dec 2020).
- It has raised $142.9M; the latest was Later Stage VC ($27.5M) in Dec 2024.
- Notable investors include Addor Capital, Cowin Capital, IDG Capital, Guotai Junan Innovation Investment, Chiron Ventures — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Ubrigene
- ·The full record, as it builds
Funding rounds
No funding rounds for Ubrigene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ubrigene
Provider of gene and cell therapy contract research services intended to assist drug development companies. The company's research focuses on GMP, CAR-T Plasmid, and various viral vectors, enabling pharmaceutical enterprises to outsource research and improve drug discovery efficiency.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2015
- Employees
- 300
- Website
- ubrigene.com/
- Ownership
- Privately Held (backing)
Ubrigene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ubrigene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ubrigene in its N-PORT filings yet. We sweep new filings monthly.